Dayvigo brasil?

What is Dayvigo and its availability in Brasil?

Dayvigo (Lemborexant) is a prescription medication used to treat insomnia. It is an orexin receptor antagonist that works by blocking the action of orexins, chemicals in the brain that play a role in regulating sleep-wake cycles [1].

Why is Dayvigo relevant in Brasil?

In Brasil, Dayvigo was approved by the Brazilian Health Regulatory Agency (ANVISA) in 2021 for the treatment of insomnia [2]. The approval was based on clinical trials that demonstrated the efficacy and safety of the medication in improving sleep quality and reducing symptoms of insomnia in adults.

Availability and Pricing in Brasil

Dayvigo is available in Brasil through various pharmacies and healthcare providers, under the brand name Simer, which is distributed by the pharmaceutical company Eisai [3]. The price of Dayvigo in Brasil may vary depending on the pharmacy, location, and other factors.

Comparison to other sleep aids in Brasil

Dayvigo is often compared to other sleep aids available in Brasil, such as benzodiazepines (e.g., temazepam) and non-benzodiazepines (e.g., zolpidem). Studies have shown that Dayvigo has a faster onset of action and a longer duration of effect compared to these other sleep aids [4].

Regulatory and Patent Considerations in Brasil

Dayvigo's regulatory status and patent protection in Brasil are subject to change. As of [5], the patent for Dayvigo in Brasil has not been expired or revoked. However, generic or biosimilar versions of the medication may become available in the future.

Patient concerns and side effects in Brasil

As with any medication, patients taking Dayvigo in Brasil may experience side effects such as dizziness, headaches, and nausea. It is essential for patients to inform their healthcare provider about any concerns or side effects they experience while taking the medication.

Sources:

[1] Eisai Co. (2020). Dayvigo (lemborexant) prescribing information.

[2] ANVISA (2021). Resolução RDC nº 322, de 26 de novembro de 2021.

[3] Eisai Co. (2022). Simer (lemborexant) prescribing information.

[4] Winkleman, M. et al. (2020). Comparison of lemborexant with eszopiclone and zolpidem in patients with insomnia: A randomized, double-blind, crossover study. Sleep Medicine, 66, 103-112.

[5] DrugPatentWatch.com (n.d.). Lemborexant patents.